COLLISION Trial – Colorectal Liver Metastases: Surgery vs Thermal Ablation

Program Status

Recruiting

Phase

Phase 3

Prior Immunotherapy Allowed

Yes

CRC-directed Trial

Yes

Tags

MSI-H/ MMRd, MSS/ MMRp

Comments

European multicenter trial comparing surgical resection and thermal ablation (radiofrequency ablation (RFA) or microwave ablation (MWA)) ) for the treatment of small-size (≤3cm) resectable colorectal liver metastases. 

Location Location Status
Netherlands
Amsterdam University Medical Center - location VUmc
Amsterdam, NH 1081
Recruiting

Contacts

MR Meijerink, MD, PhD
Contact
020 444 4444 interventieradiologie@vumc.nl

Inclusion Criteria

Most important inclusion criteria:

At least one CRLM size ≤ 3 cm eligible for both surgical resection and thermal ablation (target lesions);
Additional unresectable CRLM should be ≤ 3 cm and ablatable (unresectable lesions);
Additional unablatable CRLM should be resectable (unablatable lesions);
Maximum number of CRLM 10;
Resectability and ablatability should be re-confirmed intra-operatively by US plus full exploration for hepatic, peritoneal and regional lymph node metastases;
ASA 1-3.

Exclusion Criteria

Most important exclusion criteria:

No target lesions suitable for both resection and ablation;
Radical treatment unfeasible or unsafe (e.g. insufficient FLR);
The presence of extrahepatic nodal or non-nodal metastases;
Immunotherapy or chemotherapy ≤ 6 weeks prior to the procedure;
Any surgical resection or focal ablative liver therapy for CRLM prior to inclusion

NCT ID

NCT03088150

Date Trial Added

2017-03-23

Updated Date

2022-12-20